F. Kent. University of Washington.
Cytomegalovirus and human herpesvirus 8 DNA detection in peripheral blood monocytic cells of AIDS patients: correlations with the presence of Kaposi’s sarcoma and CMV disease discount 10mg bentyl visa gastritis working out. Nonspecific airway hyperresponsiveness in HIV disease safe bentyl 10 mg gastritis diet for. Pulmonary Complications of HIV Infection Study Group purchase bentyl 10mg without a prescription gastritis symptoms lower abdominal pain. Chest 1997, 111:121–127 Waxman A, Goldie S, Brett-Smith H, et al. Cytomegalovirus as a primary pulmonary pathogen in AIDS. Cigarette smoking in HIV infection induces a suppressive inflammatory envi- ronment in the lung. Risk factors for developing tuberculosis in HIV-1-infected adults from com- munities with a low or very high incidence of tuberculosis. Correlation of HIV-1 detection and histology in AIDS-associated emphysema. Prevalence and outcome of cytomegalovirus-associated pneumonia in rela- tion to human immunodeficiency virus infection. HIV-related Thrombocytopenia HEINZ-AUGUST HORST Thrombocytopenia is one of the most frequently observed hematological complica- tions of HIV infection. The incidence increases among patients not receiving adequate antiretroviral treatment and does not appear to vary according to the mode of acquisition of HIV (Heyward 1988, Finazzi 1990, Sloand 1992). A 10-year cumu- lative incidence of up to 45% has been reported (Eyster 1993). In patients with previously well controlled HIV infection a discontinuation of ART can lead to the rapid occurrence of thrombocytopenia (Bouldouyre 2009). Platelet counts of <30,000/µl have only been seen in less than 10% of the cases with HIV-related thrombocytopenia (Mientjes 1992, Vannappagari 2011). HIV-related thrombocytopenia has been generally attributed to two different mechanisms: First, an immunologically driven destruction of the platelets and second, an insufficient platelet production by the megakaryocytes. While in early HIV infection increased platelet destruction appears to be predomi- nant, production failure is often the main cause of thrombocytopenia in late-stage patients (Najean 1994). Table 1: Differential diagnoses of thrombocytopenia, except HIV • Pseudo-thrombocytopenia • Toxic bone marrow suppression: drugs, e. However, a spectrum of bleeding prob- lems including petechiae, epistaxis, ecchymosis, menorrhagia, hemorrhage of the gingivae may occur. Severe bleeding of the gastrointestinal tract or the CNS are rarely observed and are most likely at platelet counts <30,000/µl. In contrast to patients with immune thrombocytopenic purpura (ITP) patients often present with splenomegaly and lymph node enlargement. Spontaneous remissions of HIV-related thrombocytopenia have been observed in 10–20% of the cases, mostly with mild thrombocytopenias (Walsh 1985, Abrams 1986). Recently, the evaluation of the EuroSIDA data showed a possible association between thrombocytopenia and non-AIDS-related cancer (Borges 2014). Diagnosis HIV-related thrombocytopenia is a repeatedly confirmed isolated decrease of the platelet count <100,000/µl. In the peripheral blood the platelets often show an increased variability in size. In the bone marrow the number of megakaryocytes is normal or increased. HIV-related thrombocytopenia has to be distinguished from cases of EDTA-induced pseudo-thrombocytopenia and from other causes of “true” secondary thrombocy- topenias, which include myelotoxic drugs, hepatitis C virus (HCV), cytomegalovirus (CMV) and Mycobacterium avium complex (MAC) infections. The risk of heparin- induced thrombocytopenia is probably increased in HIV+ patients (Thompson 2007). Furthermore, the distinction from thrombotic thrombocy- topenic purpura (TTP) and hemolytic uremic syndrome is of great importance. These diseases show a peripheral platelet destruction not related to an immune mecha- nism, occur in higher frequency with HIV infection, and are life threatening. Important causes of thrombocytopenia are summarised in Table 1. Therapy The therapy is based on two principles: antiretroviral therapy, and in severe cases an additional treatment with agents used in non-HIV immune thrombocytopenia, i. In refractory cases splenectomy is also a treatment option (George 1996, Godeau 2007). The treatment besides ART is based on the recent international consensus report and the guidelines of the American Society of Hematology (Provan 2010, Neunert 2011). Table 2: Therapy of HIV-related thrombocytopenia Clinical Situation Therapy Asymptomatic and ART thrombocytes >30,000/μl Thrombocytes <30,000/μl or ART plus thrombocytes <50,000/μl and First-line therapy: glucocorticoids significant mucous membrane bleeding Subsequent therapies*: intravenous immuno- globulins, anti-(Rh)D, rituximab, splenectomy Severe bleeding Platelet transfusions, high-dose glucocorticoids, intra- venous immunoglobulins, either alone or in combination * Subsequent therapies after failure of glucocorticoids should be given according to the experience of the treating physician since only a few prospective randomised studies are available (Vesely 2004) ART: leads to a significant recovery of the platelet count within three months of treatment in most patients (Arranz Caso 1999, Servais 2001). This effect is independent of the antiretrovirals utilised and the platelet count at the start of therapy (Arranz Caso 1999). Importantly, during treatment interruptions often thrombocytopenias develop, particularly in patients with a history of HIV-related thrombocytopenia (Ananworanich 2003, Bouldouyre 2009). A therapy in addition to ART is indicated for patients with a platelet count <30,000/µl or a platelet count of <50,000/µl with a significant concomitant mucous membrane bleeding or risk factors for bleeding, such as peptic ulcers or hypertension (George 1996). Glucocorticoids: are currently the standard first-line therapy of HIV-related throm- bocytopenia. After a response, which can be expected within a few days, the initial dose should be continued for 3-6 weeks. Then, depending on the platelet count, which should be kept >60,000/µl, the glucocorticoid dose should be tapered within weeks and discontinued if possible. In the case of a life-threatening bleed we recommend higher dosages (i. In order to avoid a long-lasting therapy with prednisolone or prednisone and possible side effects, a short-term protocol with high- dose dexamethasone may be used. After treatment with 40 mg of dexamethasone HIV-related Thrombocytopenia 609 for four consecutive days in patients with non-HIV immune thrombocytopenia a response can be seen in 85% of patients. A relapse does occur in 50% of the respond- ing patients within six months. These patients require a prolonged therapy with glucocorticoids or a different treatment (Cheng 2003). After four cycles of dexam- ethasone given for four days every 14 days in 74% of the patients a long-term response (median time of 8 months) can be seen (Mazzucconi 2007). Using steroids it has to be kept in mind that particularly prolonged treatment is associated with a high risk of even fatal infectious complications (Portielje 2001, Zimmer 2004). Intravenous immunoglobulins: are costly and often given after failure of gluco- corticoids, in the case of contraindications against glucocorticoids or in a situation with life-threatening bleeding. The standard dose is 1 g/kg body weight for 1–2 days. Without maintenance therapy the platelet count will decrease in most patients and it drops to the pre-treatment levels after about a month (Godeau 2007). Anti-(Rh)D: The intravenous anti-(Rh)D application is an interesting treatment option. The mechanism of action is assumed to be mediated through the destruc- tion of antibody-coated (Rh)D positive red blood cells (RBC).
SHORT action of inhaled formoterol and salbutamol on exercise-induced asthma in children purchase bentyl with mastercard stress gastritis diet. Higham MA buy bentyl now gastritis diet paleo, Sharara AM buy genuine bentyl online xango gastritis, Wilson P, Jenkins RJ, Glendenning GA, Ind 6-LONG VS. Dose equivalence and bronchoprotective effects of salmeterol and salbutamol in asthma. Salmefamol and Salbutamol in exercise- 6 induced asthma in children. Dry powder inhalers are 6-POWDER bioequivalent to metered-dose inhalers. A study using a new urinary albuterol (salbutamol) assay technique. Fenoterol versus salbutamol nebuliser solution 6-DESIGN in asthma. Hodzhev B, Kostianev S, Todorov I, Belev G, Kartev S. Individual results 1 of treatment of COPD with low doses of fenoterol compared with treatment with ipratropium bromide. Quick-relief medications for asthma Page 93 of 113 Final Report Update 1 Drug Effectiveness Review Project Citation Exclusion Code Hogan TJ, Geddes R, Gonzalez ER. An economic assessment of 6 inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease. A comparative clinical trial of metaproterenol and 6 isoproterenol as bronchodilator aerosols. Hoskyns EW, Thomson A, Decker E, Hutchins A, Simpson H. Effect of 3 controlled release salbutamol on nocturnal cough in asthma. Comparison of 6-POWDER bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. A crossover comparison of isoproterenol, 6 metaproterenol and isoetharine by spirometric determinations. Clinical comparison of terbutaline and isoprenaline 6 administered by inhalation. Comparison of fenoterol, ipratropium bromide, and 6 their combination in patients with asthma or chronic airflow obstruction. Hultquist C, Ahlstrom H, Kjellman NI, Malmqvist LA, Svenonius E, Melin 6-POWDER S. A double-blind comparison between a new multidose powder inhaler (Turbuhaler) and metered dose inhaler in children with asthma. Hultqvist C, Ahlstrom H, Kjellman NI, Malmqvist LA, Svenonius E. A 5 comparison between bricanyl turbuhaler and bricanyl dose aerosol (MDI) in children with asthma. Hypokalemia and salbutamol 6-DESIGN therapy in asthma. Supraventricular tachycardia after 6-DESIGN fenoterol inhalation: report of two cases. The effects of ipratropium bromide and 1 salbutamol on the isolated hyperinflation during symptomfree periods in asthmatic children. Asthma specific quality 6 of life scale in a study of salmeterol hydroxynaphthoate. Levalbuterol inhibits human airway 6-DESIGN smooth muscle cell proliferation: therapeutic implications in the management of asthma. Comparative dose-response 6 study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Quick-relief medications for asthma Page 94 of 113 Final Report Update 1 Drug Effectiveness Review Project Citation Exclusion Code Ikeda A, Nishimura K, Koyama H, et al. Comparison of the 6-POWDER bronchodilator effects of salbutamol delivered via a metered-dose inhaler with spacer, a dry-powder inhaler, and a jet nebulizer in patients with chronic obstructive pulmonary disease. Imhof E, Elsasser S, Karrer W, Grossenbacher M, Emmons R, 6 Perruchoud AP. Comparison of bronchodilator effects of fenoterol/ipratropium bromide and salbutamol in patients with chronic obstructive lung disease. SHORT Turbuhaler as reliever medication compared with terbutaline in moderate asthma. Terbutaline via pressurised metered 6-POWDER dose inhaled (P-MDI) and Turbuhaler in highly reactive asthmatic patients. A comparative trial of atrovent and 6 ventolin in chronic bronchitis. Broncholytic effect of salbutamol, 1 ventolin and berotec aerosols in bronchial asthma. Bronchodilator 2 intake and plasma levels on admission for severe acute asthma. Exacerbations of 5 asthma in patients on salmeterol. Comparison of albuterol and 6 isoproterenol aerosols in bronchial asthma. The debate on S-enantiomers of beta-agonists: tempest in a 5 teapot or gathering storm? Subsensitivity of beta 3 responses during therapy with a long-acting beta-2 preparation. Objective and 3 subjective tremor responses to oral beta 2 agents on first exposure. Relative bronchodilatory responsiveness attributable 6 to sympathetic and parasympathetic activity in bronchial asthma. Clinical experience with terbutaline sulphate and 6 ipratropium bromide in bronchial asthma. Quick-relief medications for asthma Page 95 of 113 Final Report Update 1 Drug Effectiveness Review Project Citation Exclusion Code Jiro M, et al. Evaluation of the Clinical Efficacy of Berotec Tablet 1 (Fenoterol Hydrobromide) in Patients with Bronchial Asthma. Turbuhaler (R): a new device for dry powder 6-POWDER terbutaline inhalation. A comparison of fenoterol (Berotec) and salbutamol (Ventolin.
Fortunately buy discount bentyl 10mg on-line distal gastritis definition, insights into IRF4 (MUM1) gene that is transiently induced during normal the molecular taxonomy of DLBCL has led to the identiﬁcation of lymphocyte activation and is necessary for antigen receptor–driven “driver” pathways discount bentyl on line gastritis symptoms in telugu, druggable targets best buy for bentyl diet with gastritis, and more effective immuno- B-cell proliferation. A noteworthy feature of ABC DLBCL is the chemotherapy regimens, which highlights the importance of conduct- expression of bcl-2 that is induced 30-fold during peripheral ing studies within the molecular DLBCL subtypes. GCB DLBCL appears to arise from GCB cells, Conceptual therapeutic advances usually emerge from biological whereas ABC DLBCL likely arises from post-GCB cells that foundations. The major genetic and biological insights have been are blocked during plasmacytic differentiation. Clinically, GCB codiﬁed into the diagnostic criteria of the World Health Organiza- DLBCL has a higher overall survival compared with ABC DLBCL with R-CHOP–based treatment (Figure 1B). The classiﬁcation of DLBCL has been among the greatest beneﬁciaries of recent biological discoveries in lymphoid tumors. Although it has PMBL is the third molecular subtype of DLBCL, which occurs mostly in young patients (Figure 1A). As a result, treatment strategies have depended and still all of which can confound an accurate diagnosis. Two studies using depend on clinical features such as stage and age as validated by the GEP have conﬁrmed the unique biological identity of PMBL and International Prognostic Index (IPI) score. However, with the have shown a strong relationship between PMBL and nodular sclerosis application of large-scale GEP, DLBCL is now divided into at least Hodgkin lymphoma. Unlike other types of DLBCL, PMBL tumors 584 American Society of Hematology Figure 1. Since then, anthracyclines have been an essential drug class for DLBCL. However, the empiric addition of drugs to CHOP did not improve the outcome of DLBCL, as shown by the landmark randomized The GELA group recently reported a randomized study of dose- study comparing CHOP with second- and third-generation regimens intense R-ACVBP (rituximab plus doxorubicin, cyclophosphamide, in 1993. The Deutsche vindesine, bleomycin, prednisone) versus R-CHOP-21 in patients under 60 years of age with low-risk IPI. Although this study conﬁrms that younger patients and CHOP-14 in older patients. Other dose-intensity approaches have Hematology 2013 585 also been studied as initial therapy in DLBCL. A dose-intensiﬁed R-CHOP showed a failure-free survival of 65% at 3 years in high-risk DLBCL, but was associated with several toxic deaths, suggesting that it is not an optimal approach. The DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincris- tine, cyclophosphamide, doxorubicin, rituximab) regimen was devel- oped from in vitro modeling of drug resistance and drug pharmaco- dynamics and employs infusional drug scheduling, topoisomerase II targeting, and pharmacodynamic dosing. A multicenter Cancer and Leukemia Group B (CALGB) cooperative group study of 69 patients reported a 5-year time to progression and overall survival of 81% and 88%, respectively. Inhibition of NF- B may promote ABC DLBCL cell death. DA-EPOCH-R was also assessed within the 27 patients with relapsed/refractory ABC and GCB DLBCL. Overall GCB and post-GCB molecular subtypes; time to progression was survival of patients with ABC or GCB DLBCL showed a median survival 100% in GCB and 67% in non-GCB DLBCL at 62 months. Patients with ABC phase 2 trials have reported similarly promising results with DLBCL also had a signiﬁcantly higher complete and overall response DA-EPOCH-R. Although the DA- toxic to cell lines with chronic active BCR signaling (Figure 2). Activated B-cell DLBCL Based on these studies, a phase 2 multicenter study of ibrutinib was The constitutive activation of NF- B activates genes that are performed in patients with relapsed/refractory DLBCL. The objectives characteristic of ABC DLBCL promotes survival and proliferation. Seventy patients were enrolled with a median kinase inhibitor, which is necessary for NF- B activation. Dunleavy age of 64 years and 3 (range 1-7) prior regimens. Overall, there were 29 et al undertook a “proof of principle” clinical study to test whether ABC, 20 GCB, and 21 unclassiﬁed/unknown patients. Twenty-three inhibition of NF- B might sensitize ABC but not GCB DLBCL to percent of patients responded; 41% ABC and 5% GCB DLBCL chemotherapy. The investigators also assessed the relation- relapsed/refractory DLBCL. Tumor tissue was analyzed to identify ship between mutations and overall response rate (Figure 4). Patients with ABC DLBCL had a were documented in 71% (5/7) of patients with mutant CD79B and signiﬁcantly higher response (83% vs 13%; P. Interestingly, 80% (4/5) of patients GCB DLBCL (Figure 2). These results provide a rational therapeu- with both mutant CD79B and MYD88 responded, whereas patients tic approach based on genetically distinct DLBCL subtypes. Several with wild-type CD79B and mutant MYD88 did not respond, suggest- randomized studies of R-CHOP with or without bortezomib in ing a MYD88-independent pathway for NF- B activation. Patients untreated DLBCL patients have been initiated. As a single agent, lenalidomide demonstrated a PKC is a serine/threonine kinase ampliﬁed through the BCR response rate of 55% in patients with ABC DLBCL compared with signaling pathway that may also play an essential role in the only 9% in patients with GCB DLBCL, suggesting differential activation of the NF- B pathway in B cells (Figure 4). Enzastaurin is a potent oral inhibitor of PKC that has been IRF4, which requires the expression of the E3 ubiquitin ligase studied in relapsed/refractory DLBCL and in combination with complex coreceptor protein cereblon. R-CHOP in patients with intermediate- and high-risk DLBCL. It is also important to understand and target upstream targets involved in NF- B activation (Figure 3). Chronic BCR signaling and activating Studies have also targeted the PI3K/AKT/mTOR signaling pathway mutations of CARD11 and MYD88 promote NF- B activation, using mTOR inhibitors. Although the patients have been heteroge- suggesting several targets. One potential target is Bruton tyrosine neous, mTOR inhibitors (temsirolimus and everolimus) have in- kinase (Btk), in which the selective inhibitor ibrutinib is selectively duced complete remissions across lymphoma subtypes. BCR and MYD88 signaling pathways and potential targets. Signaling also activates the AKT/MTOR and MAP kinase pathways. Constitutive MYD88 signaling is an alternative pathway leading to NF- B activation. Although GCB DLBCL has a better prognosis than ABC DLBCL, Although the ideal target for the PI3K/AKT/mTOR pathway is upwards of 30% of patients are not cured with R-CHOP–based unknown, investigators are targeting upstream molecules such as treatment (Figure 1A). Bcl-6 is a key transcription factor expressed AKT and PI3K. GS 1101 is a potent small-molecule inhibitor of by GCBs, including GCB DLBCL, that regulates cell growth and PI3K p110 that blocks constitutive PI3K signaling in vitro. Bcl-6 suppresses genes that are involved in lymphocyte 1101 was studied in 9 patients with DLBCL and was well tolerated, activation, differentiation, and cell cycle arrest and the DNA but did not result in clinical responses.
Efficacy of 1 week omeprazole or lansoprazole amoxycillin clarithromycin therapy for Helicobacter pylori infection in the Japanese population best purchase for bentyl gastritis erosive. Impact of rabeprazole buy discount bentyl on-line gastritis symptoms getting worse, a new proton pump inhibitor order bentyl 10 mg online chronic gastritis operation, in triple therapy for Helicobacter pylori infection comparison with omeprazole and lansoprazole. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. Murakami K, Okimoto T, Kodama M, Sato R, Watanabe K, Fujioka T. Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Dual versus triple therapy in eradication of Helicobacter pylori. Helicobacter pylori eradication with proton pump inhibitor based triple therapies and re treatment with ranitidine bismuth citrate based triple therapy. Cure rates obtained with five different Helicobacter pylori eradication protocols in patients with duodenal ulcer: A prospective, open-label, randomized study in a primary care setting in Turkey. Current Therapeutic Research, Clinical & Experimental. Seven-day therapy for Helicobacter pylori in the United States. Veldhuyzen van Zanten S, Lauritsen K, Delchier JC, et al. One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. Proton pump inhibitors Page 86 of 121 Final Report Update 5 Drug Effectiveness Review Project 195. Rabeprazole-based 3-day and 7-day triple therapy vs. Rabeprazole- versus esomeprazole-based eradication regimens for H. Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer. Age-dependent eradication of Helicobacter pylori with dual therapy. Anagnostopoulos GK, Tsiakos S, Margantinis G, Kostopoulos P, Arvanitidis D. Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study. Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. Effects of genetic differences in CYP2C19 status on cure rates of Helicobacter pylori infection by dual rabeprazole/amoxicillin therapy in comparison with dual omeprazole/amoxicillin therapy. Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer. A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori. Systematic review: direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease Aliment Pharmacol Ther. Tindberg Y, Casswall TH, Blennow M, Bengtsson C, Granstrom M, Sorberg M. Helicobacter pylori eradication in children and adolescents by a once daily 6-day treatment with or without a proton pump inhibitor in a double-blind randomized trial. Effective maintenance treatment of reflux esophagitis with low dose lansoprazole. A randomized, double blind, placebo controlled trial. Daily omeprazole surpasses intermittent dosing in preventing relapse of oesophagitis: a US multi-centre double-blind study. Proton pump inhibitors Page 87 of 121 Final Report Update 5 Drug Effectiveness Review Project 209. Prevention of relapse of gastro-oesophageal reflux disease by lansoprazole: 30 mg every other day or 15 mg daily? Sontag SJ, Kogut DG, Fleischmann R, Campbell DR, Richter J, Haber M. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. Escourrou J, Deprez P, Saggioro A, Geldof H, Fischer R, Maier C. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. Caos A, Moskovitz M, Dayal Y, Perdomo C, Niecestro R, Barth J. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo- controlled study of efficacy and safety. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: A 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Zacny J, Zamakhshary M, Sketris I, Veldhuyzen van Zanten S. Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Proton pump inhibitors Page 88 of 121 Final Report Update 5 Drug Effectiveness Review Project 222. Cibor D, Ciecko-Michalska I, Owczarek D, Szczepanek M.